Hyperkalemic periodic paralysis

New US product, ORMALVI™ (dichlorphenamide) tablets, launches for Primary Periodic Paralysis (PPP) treatment

Retrieved on: 
Wednesday, May 8, 2024
FDA, General Health, Pharmaceutical, Health, Fetus, Cardiomyopathy, Torrent, Acidosis, Respiratory acidosis, Full, Diclofenamide, Risk, Pregnancy, Cognitive disorder, Milk, Aspirin, Metabolic acidosis, Dysgeusia, Hyperkalemia, Aplastic anemia, Partnership, PPP, Agranulocytosis, Anorexia nervosa, Human, Carbonic anhydrase inhibitor, SVP, Tablet, Incidence, Patient, Nursing, Lethargy, Serum, Hyperkalemic periodic paralysis, Diagnosis, Myopathy, Hypokalemic periodic paralysis, Paralysis, Paresthesia, Cycle, Stevens–Johnson syndrome, Hypokalemia, Quality of life, Argyreia nervosa, Sulfonamide, Coma, Pharmaceutical industry

We want to provide them with the support that they require to effectively manage their PPP.

Key Points: 
  • We want to provide them with the support that they require to effectively manage their PPP.
  • ORMALVI™ is an oral carbonic anhydrase inhibitor indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.
  • Simply Stated: Research Updates in Periodic Paralysis - Quest | Muscular Dystrophy Association [online] Available at: https://mdaquest.org/simply-stated-research-updates-in-periodic-paralysis Accessed 23 Nov. 2023.
  • The impact of permanent muscle weakness on quality of life in periodic paralysis: a survey of 66 patients.

Strongbridge Biopharma plc Announces Publication of Long-term Efficacy and Safety Results for KEVEYIS® (dichlorphenamide) for the Treatment of Primary Periodic Paralysis in Muscle & Nerve

Retrieved on: 
Tuesday, July 13, 2021
Rare diseases, Branches of biology, Organ systems, Musculoskeletal disorders, Channelopathies, Electrolyte disturbances, Nephrology, Potassium, Hypokalemic periodic paralysis, Periodic paralysis, Hyperkalemic periodic paralysis, Diclofenamide

The results confirmed that long-term treatment with KEVEYIS is safe and effective for chronic use.

Key Points: 
  • The results confirmed that long-term treatment with KEVEYIS is safe and effective for chronic use.
  • Collectively, these results reinforce the utility of KEVEYIS as an effective option in treating PPP, a life-long rare, hereditary skeletal muscle disorder that leads to debilitating attacks of muscle weakness.
  • KEVEYIS (dichlorphenamide) is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.
  • The companys rare neuromuscular franchise includes KEVEYIS (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis.

Strongbridge Biopharma plc Presents KEVEYIS® (dichlorphenamide) Primary Periodic Paralysis (PPP) Data at the 2019 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting

Retrieved on: 
Thursday, October 17, 2019
Rare diseases, Health, Channelopathies, MedWatch, Periodic paralysis, Hypokalemic periodic paralysis, Food and Drug Administration, Diclofenamide, Hyperkalemic periodic paralysis

Poster 102Long-Term Efficacy and Adverse Event Characterization ofDichlorphenamide for the Treatment of Primary Periodic Paralysis;Nicholas E. Johnson et al.

Key Points: 
  • Poster 102Long-Term Efficacy and Adverse Event Characterization ofDichlorphenamide for the Treatment of Primary Periodic Paralysis;Nicholas E. Johnson et al.
  • KEVEYIS(dichlorphenamide) is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.
  • You are encouraged to report side effects to Strongbridge Biopharma at 1-855-324-8912, or to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch .
  • Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in such statements.